Compare Wayfair Inc (W) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wayfair Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Wayfair Inc trades at $104.35 (market cap $14.14B), while State Street SPDR S&P Biotech ETF trades at $159.13. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| W | XBI | |
|---|---|---|
Market Cap | $14.14B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $119.05 | $164.28 |
52-Week Low | $57.40 | $86.92 |
Enterprise Value | $16.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $102.14, down 1.15% today but showing strong technical momentum with a recent golden cross signal. The company reported Q2 2026 earnings of $0.95 per share, beating estimates, with 7.5% revenue growth driven by U.S. market share gains. Despite negative net margins, operating cash flow improved to $665M in 2026, and analyst sentiment remains bullish with 51.8% buy ratings.
The outlook is cautiously optimistic with strong U.S. growth and margin expansion potential, but risks include persistent net losses, high debt-to-asset ratio of 95.1%, and international segment weakness. The consensus price target of $122 suggests 19% upside if execution improves.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
